ACM
ADAR1 Capital Management Portfolio holdings
AUM
$616M
This Quarter Return
-5.04%
1 Year Return
+26.77%
3 Year Return
–
5 Year Return
–
10 Year Return
–
AUM
$497M
AUM Growth
+$497M
(+36%)
Cap. Flow
+$71.1M
Cap. Flow
% of AUM
14.31%
Top 10 Holdings %
Top 10 Hldgs %
61.21%
Holding
306
New
59
Increased
87
Reduced
47
Closed
53
Top Buys
| 1 |
Cytokinetics
CYTK
|
$29M |
| 2 |
Protagonist Therapeutics
PTGX
|
$28.4M |
| 3 |
BridgeBio Pharma
BBIO
|
$18.1M |
| 4 |
Roivant Sciences
ROIV
|
$14.4M |
| 5 |
Royalty Pharma
RPRX
|
$12.1M |
Top Sells
| 1 |
Alnylam Pharmaceuticals
ALNY
|
$43.3M |
| 2 |
MACK
Merrimack Pharmaceuticals, Inc.
MACK
|
$13.3M |
| 3 |
Sarepta Therapeutics
SRPT
|
$4.21M |
| 4 |
EDR
Endeavor Group Holdings, Inc.
EDR
|
$3.91M |
| 5 |
FUSN
Fusion Pharmaceuticals Inc. Common Shares
FUSN
|
$3.78M |
Sector Composition
| 1 | Healthcare | 85.86% |
| 2 | Financials | 1.87% |
| 3 | Industrials | 0.23% |
| 4 | Utilities | 0.18% |
| 5 | Materials | 0.12% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
151
Pasithea Therapeutics
KTTA
$6.36M
| $140K | 0.03% |
27,696
| – | – |
|
152
Bolt Biotherapeutics
BOLT
$9.29M
| $139K | 0.03% |
185,999
+180,999
| +3,620% | +$136K |
|
153
Prothena Corp
PRTA
$452M
| $124K | 0.02% |
5,988
| – | – |
|
|
EGRX
154
DELISTED
Eagle Pharmaceuticals, Inc.
EGRX
| $123K | 0.02% |
+22,000
| New | +$123K |
|
155
Pliant Therapeutics
PLRX
$105M
| $108K | 0.02% |
+10,000
| New | +$108K |
|
156
Viridian Therapeutics
VRDN
$1.59B
| $104K | 0.02% |
8,000
+5,450
| +214% | +$70.9K |
|
157
Terns Pharmaceuticals
TERN
$651M
| $102K | 0.02% |
15,000
+10,000
| +200% | +$68.1K |
|
158
Scholar Rock
SRRK
$3.3B
| $100K | 0.02% |
+12,000
| New | +$100K |
|
159
TG Therapeutics
TGTX
$5.03B
| $99.4K | 0.02% |
5,589
+1,228
| +28% | +$21.8K |
|
160
Equillium
EQ
$66.8M
| $97.6K | 0.02% |
140,775
-58,000
| -29% | -$40.2K |
|
|
KCGI
161
DELISTED
Kensington Capital Acquisition Corp. V
KCGI
| $94.2K | 0.02% |
8,500
-500
| -6% | -$5.54K |
|
162
Bausch + Lomb
BLCO
$5.18B
| $92.9K | 0.02% |
6,400
+1,100
| +21% | +$16K |
|
163
Algonquin Power & Utilities
AQN
$4.32B
| $87.9K | 0.02% |
15,000
-22,000
| -59% | -$129K |
|
164
Forte Biosciences
FBRX
$138M
| $85.5K | 0.02% |
159,258
-11,252
| -7% | -$6.04K |
|
165
PMV Pharmaceuticals
PMVP
$82.1M
| $81K | 0.02% |
50,000
+40,000
| +400% | +$64.8K |
|
|
NNAGU
166
DELISTED
99 Acquisition Group Inc. Unit
NNAGU
| $80.6K | 0.02% |
7,500
| – | – |
|
|
AITRU
167
DELISTED
AI TRANSPORTATION ACQUISITION CORP Unit
AITRU
| $78.8K | 0.01% |
7,500
| – | – |
|
168
Adverum Biotechnologies
ADVM
$68.2M
| $77.5K | 0.01% |
11,300
+8,500
| +304% | +$58.3K |
|
|
IMA
169
ImageneBio, Inc. Common Stock
IMA
$153M
| $77K | 0.01% |
46,685
+11,685
| +33% | +$19.3K |
|
170
Ligand Pharmaceuticals
LGND
$3.25B
| $75K | 0.01% |
890
-25,910
| -97% | -$2.18M |
|
171
Nurix Therapeutics
NRIX
$723M
| $73K | 0.01% |
3,500
-32,108
| -90% | -$670K |
|
172
Ionis Pharmaceuticals
IONS
$9.64B
| $71.5K | 0.01% |
1,500
-1,400
| -48% | -$66.7K |
|
173
Quince Therapeutics
QNCX
$86.5M
| $69.7K | 0.01% |
92,958
+66,129
| +246% | +$49.6K |
|
174
Howard Hughes
HHH
$4.55B
| $64.8K | 0.01% |
1,000
| – | – |
|
175
Mitek Systems
MITK
$444M
| $62.6K | 0.01% |
5,600
| – | – |
|